O-carboxymethylchitosan-based novel gatifloxacin delivery system

被引:29
作者
Zhu, Aiping [1 ]
Jin, Wenjie
Yuan, Lanhua
Yang, Gongjun
Yu, Hui
Wu, Hao
机构
[1] Yangzhou Univ, Coll Chem & Chem Engn, Yangzhou 225002, Peoples R China
[2] Yangzhou Univ, Coll Vet Med, Yangzhou 225005, Peoples R China
关键词
O-carboxymethylchitosan; gatifloxacin; the minimum inhibitory concentration; Staphylococcus; Escherichia coli;
D O I
10.1016/j.carbpol.2006.08.007
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The increase in the treatment efficacy due to the enhanced permeability and retention properties and the decrease in the minimum inhibitory concentration (MIC) are the vital challenges related to the administration of the antibiotic drugs. In the present paper, we describe a novel delivery system of gatifloxacin (GFLX) from O-carboxymethylchitosan (OCNICS). GFLX is a fourth-generation fluoroguinolone, which has shown promise with excellent activity against both Gram-positive cocci and Gram-negative bacteria both in vitro and in vivo. OCMCS is a biocompatible amphiphilie derivative of chitosan. GFLX could be entrapped into OCNICS by the interaction between OCMCS and GFLX, which was characterized by fluorescence spectrum, transmission electron microscope, and dynamic light scattering techniques. The release behaviors of GFLX from this proposed delivery system in phosphate-buffered saline (PBS) solution at 37 degrees C were studied by fluorescence spectroscopy. The MIC of OCMCS formulation was evaluated. The results demonstrate that the release of GFLX from OCMCS formulation is slower than that from GFLX solution. In vitro bacteria antiproliferative activity assay confirms that the MIC of OCMCS formulation against Gram-negative bacteria is fourfold lower than the system without OCNICS. However, it seems that OCMCS has insignificant effect against Gram-positive bacteria. These results suggest that OCMCS matrix has obvious "transmission effect" on Gram-negative bacteria. (c) 2007 Published by Elsevier Ltd.
引用
收藏
页码:693 / 700
页数:8
相关论文
共 36 条
[1]   Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion [J].
Andersson, M ;
Löfroth, JE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 257 (1-2) :305-309
[2]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[3]   Biodegradable amphiphilic multiblock copolymers and their implications for biomedical applications [J].
Bae, YH ;
Huh, KM ;
Kim, Y ;
Park, KH .
JOURNAL OF CONTROLLED RELEASE, 2000, 64 (1-3) :3-13
[4]   Rat osteoblast functions on the o-carboxymethyl chitosan-modified poly(D,L-lactic acid) surface [J].
Cai, KY ;
Yao, KD ;
Li, Z ;
Yang, ZM ;
Li, XQ .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2001, 12 (12) :1303-1315
[5]  
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[6]  
2-4
[7]   Emerging ciprofloxacin-resistant Pseudomonas aeruginosa [J].
Chaudhry, NA ;
Flynn, HW ;
Murray, TG ;
Tabandeh, H ;
Mello, MO ;
Miller, D .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1999, 128 (04) :509-510
[8]   Polymer vesicles [J].
Discher, DE ;
Eisenberg, A .
SCIENCE, 2002, 297 (5583) :967-973
[9]   Simulation of skin permeability in chitosan membranes [J].
Dureja, H ;
Tiwary, AK ;
Gupta, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 213 (1-2) :193-198
[10]   Enzymatic biodegradation of poly(ethylene oxide-b-ε-caprolactone) diblock copolymer and its potential biomedical applications [J].
Gan, ZH ;
Jim, TF ;
Li, M ;
Yuer, Z ;
Wang, SG ;
Wu, C .
MACROMOLECULES, 1999, 32 (03) :590-594